On August 22, 2019 Immunowake reported the company has raised $3M in financing, led by Changchun High-tech Industries Group Inc (SZSE: 000661) (Press release, Immunowake, AUG 22, 2019, View Source [SID1234656118]). This investment will be used to accelerate the research, development, and commercialization of Immunowake’s portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immunowake is a pre-clinical company focused on the development of antibody-based therapeutics against cancer. Immunowake’s CEO and founder Xiaoyun Wu said, "This financing will allow us to advance our pipeline and further improve our antibody platform, which will be critical in identifying and developing future products. This investment symbolizes a high level of confidence in our technology."